Biogen Idec and Abbott Announce Enrollment of First Patient in Global Phase III Study of Daclizumab for Relapse-Remitting Multiple Sclerosis Biogen Idec, 24 May 2010 Accessed on 3 Dec 2011 from http://www.biogenidec.com/press_release_details.aspx?ID=5981&ReqId=1430324. CommentRecommendBookmarkWatch